title: In vitro pharmacodynamic profile of Loranthus ferrugineus: evidence for noncompetitive antagonism of norepinephrine-induced vascular contraction.
abstract: The mode by which Loranthus ferrugineus methanol extract antagonizes and/or modulates norepinephrine-induced vasoconstriction was investigated in rat aortic rings. The vascular effects of three different concentrations of this extract were challenged against cumulative additions of norepinephrine. Phentolamine, a nonselective α-adrenoceptor antagonist, verapamil, an L-type calcium channel blocker, and papaverine, a phosphodiesterase inhibitor, were used in three different concentrations as positive controls. Log concentration-response curves and double-reciprocal plots were constructed for the extract and each vasorelaxant. To characterize antagonism reversibility, the norepinephrine maximum contractile effect was examined before extract addition to the aortic ring chamber and after its removal. Phentolamine shifted the norepinephrine log concentration-response curve to the right with no significant depression in the maximum response. Similar to verapamil and papaverine, the extract produced a rightward shift in norepinephrine log concentration-response curve and a significant drop in maximum response. The double-reciprocal plots showed comparable y-intercept values for all phentolamine concentrations, a characteristic of competitive antagonism. In contrast, different y-intercept values on double-reciprocal plots were obtained for each concentration of extract, verapamil, and papaverine, typical of noncompetitive antagonism. The norepinephrine maximum contractile response was approximately similar before the addition of extract and after its removal. The data collectively showed that L. ferrugineus methanol extract exerted its vascular effect by reversible noncompetitive antagonism of norepinephrine-induced vasoconstriction. These findings add to the understanding of the cardiovascular mechanisms by which L. ferrugineus, a plant traditionally used for the management of hypertension, elicits its action.
authors.affiliation: School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia. omar_3m@yahoo.com
authors.forename: Omar Z
authors.initials: OZ
authors.lastname: Ameer
authors.forename: Ibrahim M
authors.initials: IM
authors.lastname: Salman
authors.forename: Hafsa S
authors.initials: HS
authors.lastname: Najim
authors.forename: Ghassan Z
authors.initials: GZ
authors.lastname: Abdullah
authors.forename: Muthanna F
authors.initials: MF
authors.lastname: Abdulkarim
authors.forename: Mun Fei
authors.initials: MF
authors.lastname: Yam
authors.forename: Amirin
authors.initials: A
authors.lastname: Sadikun
authors.forename: Mohamed Z
authors.initials: MZ
authors.lastname: Asmawi
mesh_terms: D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects / Q000502:physiology*; D004336:Drug Antagonism; D066298:In Vitro Techniques; D028183:Loranthaceae / Q000737:chemistry*; D008297:Male; D009638:Norepinephrine / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D010936:Plant Extracts / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014662:Vasoconstrictor Agents / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D014665:Vasodilator Agents / Q000493:pharmacokinetics*
chemical_list: D010936:Plant Extracts; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D009638:Norepinephrine